The atherogenic index of plasma is increased by hormonal contraception

References

• Crosignani PG for the ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006;12:483–97.
   Google Scholar
• Dubey RK, Imthurn B, Zacharia LC, Jackson EK. Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 2004; 44:789–95.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan G, Rana A, Das C, Chandra NC. Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue. Contraception 2007;76:297–305.
   Google Scholar
• Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63:1–11.
   PubMed Web of Science ®Google Scholar
• Tikkanen MJ. Role of plasma lipoprotein in the pathogenesis of atherosclerotic disease, with special reference to sex hormone effects. Am J Obstr Gynekol 1990;163:296–304.
   PubMed Web of Science ®Google Scholar
• Stampfer M, Willett W, Colditz G, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1998;319:1313–7.
   Google Scholar
• Stefanick ML, Prentice RL, Anderson G, Gass M, Manson JE, Hendrix SL, Vista-Deck D, McNeeley G. Reanalysis of the women's health initiative oral contraceptive data reveals no evidence of delayed cardivascular benefit. Fertil Steril 2005;83:853–4.
   Google Scholar
• Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endoc Metab 2005;90:3863–70.
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Merz NB. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009;53:221–31.
   PubMed Web of Science ®Google Scholar
• Suissa S. The Transnational study of oral contraceptive cardiovascular safety: history and science. J Clin Epidemiol 2009;62:588–93.
   Google Scholar
• Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007–11.
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026–33.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Ballantyne CM, Carmena R, Cabezas MC, Chapman MJ, Couture P, De Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KMS. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten country panel. J Intern Med 2006;259:247–58.
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I. The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 2006;259:493–519.
   PubMed Web of Science ®Google Scholar
• Rasouli M, Kiasari AM. The ratio of apoB/apoAl, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 2006;44:1015–21.
   PubMed Web of Science ®Google Scholar
• Castelli, W.P. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3–9.
   PubMed Web of Science ®Google Scholar
• Simons LA. Triglyceride levels and the risk of coronary artery disease: a view from Australia. Am J Cardiol 1992; 70:14–8.
   Google Scholar
• Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187–95.
   PubMed Web of Science ®Google Scholar
• Williams PT, Superko HR, Haskell WL, Alderman EL, Blanche PJ, Holl LG, Krauss RM. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003;23:314–21.
   PubMed Web of Science ®Google Scholar
• Drexel H, Aman FW, Rentsch K, Neunschwander C, Leuthy A, Khan SI, Follath F. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992;70:436–40.
   PubMed Web of Science ®Google Scholar
• Dobiasova M, Urbanova Z, Samanek M. Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate. Physiol Res 2005;54:159–65.
   PubMed Web of Science ®Google Scholar
• Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001;34: 583–8.
   PubMed Web of Science ®Google Scholar
• Dobiasova M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem 2004;50:1113–5.
   PubMed Web of Science ®Google Scholar
• Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003;49:1873–80.
   PubMed Web of Science ®Google Scholar
• Frohlich J, Dobiasova M, Adler L, Francis M. Gender differences in plasma levels of lipoprotein(a) in patients with angiographically proven coronary artery disease. Physiol Res 2004;53:481–6.
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJG, Jukema JW, Day NE, Kastelein JJP, Khaw KT. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis 2006;187: 415–22.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 1998;58:83–91.
   PubMed Web of Science ®Google Scholar
• Falsetti L, Pasinetti E. Effect of long term administration of an oral-contraceptive containing ethinylestradiol and cyproteron-acetate on lipid-metabolism in women with polycystic-ovary-syndrome. Acta Obstet Gyn Scan 1995;74: 56–60.
   PubMed Web of Science ®Google Scholar
• Loke DFM, Ng CSA, Holck S, Hall PE, Ratnam SS. Lipid and biochemical changes after low-dose oral contraception. Contraception 1992;46:227–41.
   PubMed Web of Science ®Google Scholar
• Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004;69: 271–8.
   PubMed Web of Science ®Google Scholar
• Kunz J, Jaeger A. Hormonal contraception has no effect on the atherogenicity of blood lipids: results of a prospective open-label multicenter study in 1321 patients. Praxis (Bern 1994) 1996;85:3–8.
   Google Scholar
• Shawe J, Lawrenson R. Hormonal contraception in women with diabetes mellitus: special considerations. Treat Endocrinol 2003;2:321–30.
   PubMedGoogle Scholar
• Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71: 409–16.
   PubMed Web of Science ®Google Scholar
• Scharnagl H, Petersen G, Nauck M, Teichmann AT, Wieland H, Marz W. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 mg or 30 mg) and levonorgestrel (100 mg or 150 mg) on lipoprotein metabolism. Contraception 2004;69:105–13.
   PubMed Web of Science ®Google Scholar
• Guazzelli CA, Lindsey PC, de Araujo FF, Barbieri M, Petta CA, Aldrighi JM. Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives. Contraception 2005;71:118–21.
   Google Scholar
• Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-1 ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355–63.
   PubMed Web of Science ®Google Scholar
• Ng YW, Liang S, Singh K. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism–a randomized comparative study. Contraception 2009;79:24–8.
   PubMedGoogle Scholar
• Loos RJF, Verhaeghe J, de Zegher F, Beunen G, Derom C, Fagard R, Mathieu C, Vlietinck R. Markers for cardiovascular diseases in monozygotic twins discordant for the use of third-generation oral contraceptives. J Hum Hypertens 2003;17:481–5.
   Google Scholar
• Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241–53.
   PubMed Web of Science ®Google Scholar
• Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas’ Atherosclerosis regression study (STARS). Metabolism 1993;42:1461–7.
   Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–9.
   PubMed Web of Science ®Google Scholar
• Zieske AW, Tracy RP, McMahan A, Herderick EE, Homma S, Malcolm GT, McGill HC, Strong JP. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscl Throm Vas 2005;25:1–7.
   Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213–9.
   PubMedGoogle Scholar
• Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81:7B–12B.
   PubMed Web of Science ®Google Scholar
• Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993;34:1687–97.
   PubMed Web of Science ®Google Scholar
• Murakami T, Michelagnoli S, Longhi R, Gianfranceschi G, Pazzucconi F, Calabresi L, Sirtori CR, Franceschini G. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1819–28.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882–8.
   PubMed Web of Science ®Google Scholar
• Ohta T, Kakiuti Y, Kurahara K, Saku K, Nagata N, Matsuda I. Fractional esterification rate of cholesterol in high density lipoprotein is correlated with low density lipoprotein particle size in children. J Lipid Res 1997;38:139–46.
   Google Scholar
• Ohta T, Saku K, Takata K, Nagata N, Maung KK, Matsuda I. Fractional esterification rate of cholesterol in high density lipoprotein (HDL) can predict the particle size of low density lipoprotein and HDL in patients with coronary heart disease. Atherosclerosis 1997;135:205–12.
   Google Scholar
• Ohta T, Kakiuti Y, Kurahara K, Saku K, Nagata N, Matsuda I. Fractional esterification rate of cholesterol in high density lipoprotein is correlated with low density lipoprotein particle size in children. J Lipid Res 1997;38:139–46.
   Google Scholar
• Dobiasova M, Urbanova Z, Rauchova H, Samanek M, Frohlich J. High-density lipoprotein subclasses and esterification rate of cholesterol in children–effect of gender and age. Acta Paediatr 1998;87:918–23.
   Google Scholar
• Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 2004;50:1184–8.
   PubMed Web of Science ®Google Scholar
• Yang B, Tian H, Ren Y, Tong N, Yu H, Han L, Ran X. The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2005;22: 560–4.
   Google Scholar
• Kawai T, Funae O, Shimada A, Tabata M, Hirata T, Atsumi Y, Itoh H. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Internal Med 2008;47:1181–8.
   PubMed Web of Science ®Google Scholar
• Shand B, Scott R, Connolly S, Clarke R, Baker J, Elder P, Frampton C, Yeo J. Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes. Diabetes Obes Metab 2007;9:540–7.
   Google Scholar
• Vrablik M, Fait T, Kovar J, Poledne R, Ceska R. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 2008;57: 1088–92.
   PubMed Web of Science ®Google Scholar
• van Rooijen M, Hansson LO, Frostegard J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006;4:77–82.
   PubMed Web of Science ®Google Scholar
• Haarala A, Eklund C, Pessi T, Lehtimäki T, Huupponen R, Jula A, Viikari J, Raitakari O, Hurme M. Use of combined oral contraceptives alters metabolic determinants and genetic regulation of C-reactive protein. The Cardiovascular Risk in Young Finns Study. Scand J Clin Lab Invest 2009; 69:168–74.
   PubMed Web of Science ®Google Scholar
• Buchbinder S, Kratzsch J, Fiedler GM, Yar V, Brügel M, Leichtle A, Weber W, Alexander H, Matthes G, Thiery J. Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 2008;68:140–4.
   PubMed Web of Science ®Google Scholar
• Winkler UH, Röhm P, Höschen K. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. Contraception 2010;8:391–400
   Google Scholar
• Wiegratz I, Stahlberg S, Manthey T, Sänger N, Mittmann K, Palombo-Kinne E, Mellinger U, Lange E, Kuhl H. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use. Contraception 2010; 81:57–61.
   PubMed Web of Science ®Google Scholar